| Catalog No. | HB949026 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Human |
|---|
| Isotype | Fusion-[human activin receptor type 2-A (activin receptor type IIA, ACTR-IIA) extracellular domain (ECD) fragment (1-109) engineered varian]2-IgG1-Fc (Fragment constant) |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | ACVR2, ACTRIIA, ACTR-IIA, Activin receptor type IIA, ACVR2A, Activin receptor type-2A |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Purified by nickel column chromatography. |
|---|
| Accession | P27037 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -2118°C. |
|---|
| Alternate Names | CAS:2727114-26-1 |
|---|
| Background | Elritercept (KER-050) is a recombinant fusion protein comprising a modified activin receptor type IIA extracellular domain fused to a human IgG1 Fc. Elritercept inhibits activin A and other select TGF-β superfamily ligands. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
